OncologyEducation
@oncologyeducation.bsky.social
Evidence-based, educational resources for the oncology community. Authored exclusively by a leading international faculty of oncology.
Less travel. Less time in clinic.
Oral decitabine–cedazuridine may offer a practical alternative for MDS and CMML patients needing flexible treatment options.
👀 Check out the data in our latest infographic: ow.ly/84RM50WcvWn
#MDS #CMML #Infographic #OncEd #MedOnc
Oral decitabine–cedazuridine may offer a practical alternative for MDS and CMML patients needing flexible treatment options.
👀 Check out the data in our latest infographic: ow.ly/84RM50WcvWn
#MDS #CMML #Infographic #OncEd #MedOnc
June 23, 2025 at 5:12 PM
Less travel. Less time in clinic.
Oral decitabine–cedazuridine may offer a practical alternative for MDS and CMML patients needing flexible treatment options.
👀 Check out the data in our latest infographic: ow.ly/84RM50WcvWn
#MDS #CMML #Infographic #OncEd #MedOnc
Oral decitabine–cedazuridine may offer a practical alternative for MDS and CMML patients needing flexible treatment options.
👀 Check out the data in our latest infographic: ow.ly/84RM50WcvWn
#MDS #CMML #Infographic #OncEd #MedOnc
🚨 Late-breaking from #ASCO25: Dr. Kohei Shitara presents LBA4002 – DESTINY-Gastric04! T-DXd challenges RAM+PTX in 2L HER2+ metastatic #gastriccancer & GEJA 🔬 Will this redefine the standard of care? ow.ly/bpNQ50W2SFk
#HER2Positive #ASCO2025
#HER2Positive #ASCO2025
June 2, 2025 at 7:07 PM
🚨 Late-breaking from #ASCO25: Dr. Kohei Shitara presents LBA4002 – DESTINY-Gastric04! T-DXd challenges RAM+PTX in 2L HER2+ metastatic #gastriccancer & GEJA 🔬 Will this redefine the standard of care? ow.ly/bpNQ50W2SFk
#HER2Positive #ASCO2025
#HER2Positive #ASCO2025
Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction and gastric cancers, plus key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer.
🎧 ow.ly/ZSy750VNPEp
🎧 ow.ly/ZSy750VNPEp
May 6, 2025 at 5:35 PM
Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction and gastric cancers, plus key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer.
🎧 ow.ly/ZSy750VNPEp
🎧 ow.ly/ZSy750VNPEp
Today, we celebrate #OncologyNursingDay!
Oncology nurses are integral to cancer care, providing expert treatment and unwavering support to patients and their families.
Thank you for your dedication to making a difference in the lives of those impacted by cancer. 💙
Oncology nurses are integral to cancer care, providing expert treatment and unwavering support to patients and their families.
Thank you for your dedication to making a difference in the lives of those impacted by cancer. 💙
April 1, 2025 at 6:53 PM
Today, we celebrate #OncologyNursingDay!
Oncology nurses are integral to cancer care, providing expert treatment and unwavering support to patients and their families.
Thank you for your dedication to making a difference in the lives of those impacted by cancer. 💙
Oncology nurses are integral to cancer care, providing expert treatment and unwavering support to patients and their families.
Thank you for your dedication to making a difference in the lives of those impacted by cancer. 💙
Prof. Axel Hauschild comparing the results of local therapies in the treatment of lentigo maligna melanoma. Full session here: ow.ly/wXSh50VcbBy
All sessions from Canadian Melanoma Conference 2025 here: ow.ly/3I6050VcbBx
#CMC25 #MedOnc #OncEd
All sessions from Canadian Melanoma Conference 2025 here: ow.ly/3I6050VcbBx
#CMC25 #MedOnc #OncEd
March 6, 2025 at 9:40 PM
Prof. Axel Hauschild comparing the results of local therapies in the treatment of lentigo maligna melanoma. Full session here: ow.ly/wXSh50VcbBy
All sessions from Canadian Melanoma Conference 2025 here: ow.ly/3I6050VcbBx
#CMC25 #MedOnc #OncEd
All sessions from Canadian Melanoma Conference 2025 here: ow.ly/3I6050VcbBx
#CMC25 #MedOnc #OncEd